Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Go back to Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults| (NASDAQ: PCVX) | Delayed: 47.46 +0.17 (0.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.29 | 52 Week High | $ | |||
| Open | $47.30 | 52 Week Low | $ | |||
| Day High | $48.44 | P/E | N/A | |||
| Day Low | $46.71 | EPS | $ | |||
| Volume | 1,030,979 | |||||
